About this raise
Cytonics, with a valuation of $58.9 million, is raising funds on Dealmaker Securities. The company is a leader in regenerative medicine and has developed innovative therapies for musculoskeletal diseases like osteoarthritis. Cytonics has created an Autologous Platelet Integrated Concentration system concentrating A2M from patients’ blood to treat their own damaged joints. The company has a strong IP portfolio with 22 issued US and international patents. Gaetano Scuderi founded Cytonics Corporation in July 2006. The current crowdfunding campaign has a minimum target of $25,000 and a maximum target of $1.9 million. The campaign proceeds will be used for GMP manufacturing of CYT-108, phase 1 human clinical trial, and working capital.
Investment Overview
Invested $1,695,868 :
Deal Terms
Company & Team
Company
- Year Founded
- 2006
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Distribution Model
- B2B/B2C
- Margin
- Low
- Capital Intensity
- High
Financials
- Revenue -47.9% YoY
-
$307,500
as of FY2021
- Monthly Burn
-
$1,878,682
as of FY2021
-
Runway
-
0.5 months
as of FY2021
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Company Funding & Growth
Funding history
- Total Prior Capital Raised
- $22,000,000
- Grants
- $1,600,000
- VC Backed?
- Yes
Close Date | Platform | Valuation | Total Raised | Security Type | Status | Reg Type |
---|---|---|---|---|---|---|
03/14/2026 | StartEngine | $104,080,000 | $2,448,845 | Equity - Common | Active | RegA+ |
08/25/2024 | StartEngine | $66,557,294 | $938,436 | Equity - Preferred | Funded | RegCF |
05/28/2024 | StartEngine | $65,792,080 | $3,626,034 | Equity - Preferred | Funded | RegCF |
03/31/2023 | DealMaker Securities | $58,915,995 | $1,695,868 | Equity - Preferred | Funded | RegCF |
10/14/2022 | SeedInvest | $58,915,996 | $2,633,766 | Equity - Preferred | Funded | RegCF / RegD 506(c) |
04/30/2021 | SeedInvest | $46,701,000 | $4,667,638 | Equity - Preferred | Funded | RegA+ |
05/18/2019 | SeedInvest | $32,400,000 | $494,344 | Convertible Note | Funded | RegCF / RegD 506(c) |
Growth Charts
Revenue History
Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.
Valuation History
Price per Share History
Note: Share prices shown in earlier rounds may not be indicative of any stock splits.